A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 1030
- Registration Number
- NCT04724473
- Locations
- 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States
Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% Cream
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 124
- Registration Number
- NCT04358770
- Locations
- 🇺🇸
WayCro, Dallas, Texas, United States
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 550
- Registration Number
- NCT04321070
- Locations
- 🇺🇸
Catawba Research LLC, Charlotte, North Carolina, United States
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 1260
- Registration Number
- NCT04134273
- Locations
- 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 485
- Registration Number
- NCT03880357
- Locations
- 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States
To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 1116
- Registration Number
- NCT03689010
- Locations
- 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States
An Open-Label Study to Assess Safety
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 88
- Registration Number
- NCT03645499
- Locations
- 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris
Early Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 700
- Registration Number
- NCT03433378
- Locations
- 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris
Early Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 455
- Registration Number
- NCT03427554
- Locations
- 🇺🇸
Catawba Research, LLC, Charlotte, North Carolina, United States
A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 413
- Registration Number
- NCT03257943
- Locations
- 🇺🇸
Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States
© Copyright 2024. All Rights Reserved by MedPath